• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Cardiology

Cerebral embolic protection devices not effective in surgical aortic valve repair

bySusy LamandMichael Milligan
August 11, 2017
in Cardiology, Imaging and Intervention, Neurology, Surgery
Reading Time: 3 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. This randomized clinical trial showed that cerebral embolic protection devices did not significantly reduce the risk of CNS infarction among patients with calcific aortic stenosis undergoing SAVR.

2. However, fewer patients experienced delirium at postoperative day 7 in the cerebral embolic protection devices group compared to control.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Aortic stenosis is common among elderly patients, and an increasing number of surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR) procedures are being performed each year. Despite steady procedural improvements, central nervous system (CNS) infarctions remain a serious complication with significant detrimental impacts on survival, quality of life, and health care costs. As such, cerebral embolic protection devices were developed to reduce the incidence of CNS infarction post-SAVR. Two such devices are “intra-aortic filters” and “suction-based extracters”. This randomized clinical trial found that, despite capturing debris in most patients, cerebral embolic protection devices did not reduce the rates of clinical and radiographic signs of infarction, with nearly 69% of patients experiencing infarction. Interestingly though, the rates of delirium 7 days after aortic procedure were lower in those patients who received a cerebral protection device.

This study suggests that cerebral protection devices may be of little utility during aortic replacement procedures. However, there are a few limitations to the study. First, the significance of small and silent lesions on imaging cannot be established. Second, imaging was done on day 7 post-operation, but the optimal time frame to assess the effectiveness of such an operation is within the first few postoperative days – this may have led to an overestimation of the infarct burden through capturing infarctions not directly related to the intraoperative embolization (i.e., through atrial fibrillation). Third, the use of the NIHSS score has been validated as a measure of stroke severity but is not diagnostic of a stroke. Overall, this study reports important findings that cerebral embolic protection devices do not reduce incidences of CNS infarction 7 days post-operation, but the significant reduction in rates of delirium warrant further study in a larger study population.

Click to read the study, published in JAMA

RELATED REPORTS

Apixaban (Eliquis) is associated with reduced rates of ischemic stroke and bleeding in patients with atrial fibrillation and advanced chronic kidney disease compared with warfarin (Coumadin)

Thrombectomy may improve functional independence in acute ischemic stroke with medium vessel occlusion

Relevant Reading: Clinically silent cerebral ischemic events after cardiac surgery: their incidence, regional vascular occurrence, and procedural dependence.

In-Depth [randomized control study]: This randomized clinical trial studied 383 patients aged 60 years and older undergoing SAVR. Patients were randomized into the following groups: 1) intra-aortic filtration device with a heparin-coated mesh filter (n = 133), 2) suction-based extraction (n = 118), and 3) control (n = 132), where a standard aortic perfusion cannula was used. The primary endpoint was freedom from clinical or radiographic CNS infarction at 7 days after the procedure, supplemented by serial neurological assessment using the NIHSS. The secondary endpoint was mortality, clinical ischemic stroke, or acute kidney injury within 30 days after surgery. The study found that clinical and radiographic findings of infarction were not reduced in the two different treatment groups, with nearly 69% of patients experiencing clinical or radiographic stroke. Rates of freedom from CNS infarction was not different in the suction-based extraction group and the control group (32.0% vs 33.3% respectively; between-group difference, -1.3% [95%CI, -13.8% to 11.2%]) nor between the intra-aortic filtration group and the control group (25.6% vs 32.4% respectively; between-group difference, -6.9% [95%CI, -17.9% to 4.2%]). It was, however found that delirium rates declined in the cerebral embolic protection group compared to control. At postoperative day 7, 6.3% of patients in the suction-based extraction group experienced delirium, vs 15.3% of patients in the control group (between-group difference, -9.1%, 95%CI, -17.1% to -1.0%); and 8.1% of patients in the intra-aortic filtration group vs 15.6% of patients in the control group (between-group difference, -7.4%, 95%CI, -15.5% to 0.6%).

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: aortic stenosisaortic valve replacementischemic stroke
Previous Post

Plasma Epstein–Barr virus DNA useful for nasopharyngeal carcinoma screening

Next Post

Levosimendan not effective in reducing postoperative low cardiac output syndrome in select heart surgery patients

RelatedReports

A detailed illustration of a kidney and glomeruli, with a pill depicted, representing treatment for kidney-related conditions. It suggests a focus on chronic kidney disease.
Nephrology

Apixaban (Eliquis) is associated with reduced rates of ischemic stroke and bleeding in patients with atrial fibrillation and advanced chronic kidney disease compared with warfarin (Coumadin)

September 9, 2026
Ischemic stroke collage: an engraved brain with one artery traced in teal and a small clot lifted away on a ribbon
Neurology

Thrombectomy may improve functional independence in acute ischemic stroke with medium vessel occlusion

May 26, 2026
Ischemic stroke collage: an engraved brain with one artery traced in blue beside a glass hourglass on graph paper
Weekly Rewinds

2 Minute Medicine Rewind April 20, 2026

April 20, 2026
Aortic valve disease collage: an engraved heart, a three-leaflet aortic valve seen from above and a replacement valve
Cardiology

Early surgical valve replacement offers survival benefit in asymptomatic, very severe aortic stenosis

April 3, 2026
Next Post

Levosimendan not effective in reducing postoperative low cardiac output syndrome in select heart surgery patients

Midlife smoking, diabetes, and hypertension associated with late life dementia

Antiretroviral therapy with tenofovir-emtricitabine-efavirenz demonstrates lower rate of adverse birth outcomes than other regimens

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

NPI Lookup · Free

Look up any US clinician

Search by name or NPI number, live from the CMS NPI Registry.

  • OIG exclusion check
  • Licenses and specialties
  • No account needed
Open NPI Lookup →

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Docosahexaenoic acid supplementation does not reduce risk of necrotizing enterocolitis among preterm infants
  • AI-drafted responses to patient messages linked to faster reply times but no drop in after-hours work for clinicians
  • FDA identifies safety concerns for compounded peptide injections, including reports of death
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.